Press release
The vascular disrupting agents market is projected to be worth USD 2 billion by 2030, growing at an annualized rate of over 60%, claims Roots Analysis
London
Roots Analysis has announced the addition of “Vascular Disrupting Agents Market, 2021-2030” report to its list of offerings.
Despite multiple cancer treatment options, there is an evident unmet need for anti-cancer therapies with better efficacy and less toxicity. The vascular disrupting agents, which target the established tumor vasculature and disrupt blood flow to cancerous tissue, have garnered considerable interest as a novel anticancer therapeutic modality.
To order this 290+ page report, which features 110+ figures and 125+ tables, please visit https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market.html
Key Market Insights
Currently, more than 120 vascular disrupting agents are in the development pipeline
Around 50% of the vascular disrupting agents are being evaluated in phase II clinical trials, while more than 5% are either marketed or in phase III of development. Examples of phase III drugs include Bavituximab (non-small cell lung cancer), Icaritin (hepatocellular carcinoma), NGR-TNF (malignant pleural mesothelioma), Padeliporfin (transitional cell cancer of renal pelvis and ureter), Plinabulin (non-small cell lung cancer, chemotherapy-induced neutropenia) and VB-111 (glioblastoma, recurrent platinum resistant ovarian cancer). Further, 35% molecules are in phase I trials.
Around 30 industry and non-industry players are engaged in the development of vascular disrupting agents
Around 40% of these firms are start-ups / small players (with less than 50 employees). It is also worth highlighting that, majority of the firms engaged in this domain (56%) are based in North America, followed by Asia Pacific (25%) and Europe (19%).
Over 530 clinical trials are currently evaluating the therapeutic effects of vascular disrupting agents, worldwide
It is worth mentioning that most of the trials were / are being conducted in North America (56%), where more than 40% of the total number of patients had been enrolled. This is followed by clinical research activity in Europe (24%) and Asia Pacific (20%).
Around 800 articles related to vascular disrupting agents have been published in reputed scientific journals, since 2016
More than 30% of the publications mentioned in the report, were focused on the assessment of treatment safety / effectiveness of various vascular disrupting agents. Popular journals that have published multiple articles related vascular disrupting agents, include Scientific Reports, Oncotarget, European Journal of Medicinal Chemistry, and PLoS One.
To order this 290+ page report, which features 110+ figures and 125+ tables, please visit https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market.html
Close to 220 grants have been awarded to support research on vascular disrupting agents, since 2016
An estimated USD 96 million in grants have been awarded to various companies / organizations working in this domain, during time period between 2016 and January 2021. Almost 20% of the total grant amount was funded by the National Cancer Institute.
Over 265 eminent scientists (identified as key opinion leaders (KOLs)) are involved in the clinical trials of vascular disrupting agents
Around 50% of these KOLs are associated with the organizations based in North America, followed by those in Asia Pacific (38%) and Europe (12%). Majority of these KOLs are currently affiliated to hospitals and medical centers.
The market is anticipated to grow at a CAGR of over 60%, during the period 2021-2030
Growth in this domain is anticipated to be driven by the drugs that are being developed for the treatment of non-small cell lung cancer. North America (primarily the US) and Europe are expected to capture around 50% of the market share by 2030, in terms of the sales-based revenues.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market/request-sample.html
Key Questions Answered
Who are the leading industry and non-industry players in this market?
Which cancer indications can be treated with vascular disrupting agents?
Which geographies are the most active in conducting clinical trials on vascular disrupting agents?
What is the focus area of the research activities going on in this domain?
Which are the leading administering institute centers supporting the research related to this domain?
Who are the key opinion leaders that can help you drive your development efforts?
How is the current and future market opportunity likely to be distributed across key market segments?
The USD 2 billion (by 2030) financial opportunity within the vascular disrupting agents market has been analyzed across the following segments:
Target Indication
Chemotherapy-induced Neutropenia
Glioblastoma
Hepatocellular Carcinoma
Malignant Pleural Mesothelioma
Non-Small Cell Lung Cancer
Prostate Cancer
Recurrent Platinum Resistant Ovarian Cancer
Transitional Cell Cancer of Renal Pelvis and Ureter
Therapeutic Area
Solid Tumors
Others
Type of Molecule
Small Molecules
Ligand Directed Agents
Type of Therapy
Monotherapy
Combination Therapy
Route of Administration
Oral
Intravenous
Key Geographical Regions
North America
Europe
Asia-Pacific and Rest of the World
The research includes detailed profiles of key players (listed below), each profile features an overview of the company, its financial information (if available), drug portfolio, details on recent developments, as well as an informed future outlook.
AGC Biologics
Avid Bioservices
Bionomics
Iceni Pharmaceuticals
Myrexis
Oncotelic Therapeutics
VBL Therapeutics
For additional details, please visit
https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market.html
or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. TIL-based Therapies Market, 2021-2030
2. TCR-based Therapies Market, 2021-2030
3. Peptide Therapeutics Market, 2021-2030
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The vascular disrupting agents market is projected to be worth USD 2 billion by 2030, growing at an annualized rate of over 60%, claims Roots Analysis here
News-ID: 2328906 • Views: …
More Releases from Roots Analysis
Respiratory syncytial virus infections are recognized among the prevalent respir …
Currently, several traditional techniques are available for treating these infections, although none of them have been competent enough to reduce the healthcare burden of RSV diseases. In order to address this, RSV vaccines emerged as a promising alternative, which provides active immunity against the RSV infections, thus protecting the vulnerable population. Further, by providing targeted immunity, these vaccines help reducing the severity of RSV infections and lower the hospitalization rates…
Rise in demand of glp-1 drugs for metabolic disorders.
In recent years, owing to its broader clinical potential in the treatment of obesity and type 2 diabetes, along with their proven efficacy in reducing cardiovascular risks, GLP-1 drugs market has garnered significant traction within the medical science domain.
Concurrently, the rising demand and escalating prevalence of metabolic disorder including type 2 diabetes and obesity are fueling the need for treatments capable of effectively managing these conditions. This trend is expected…
Carbon footprint management market is Set to Soar to USD 55.9 Billion by 2035
Carbon footprint refers to the measurement of greenhouse gas emissions, expressed in carbon dioxide equivalent. It is released into the atmosphere either directly or indirectly through various activities, processes, or products. These emissions originate from diverse sources, including energy consumption, manufacturing processes, transportation networks, and waste management strategies.
The global carbon footprint management market, valued at USD 12.2 billion in 2024, is expected to reach USD 13.5 billion in 2025…
Gene switches have garnered significant attention from drug developers owing to …
The global gene switch market size is estimated to grow from USD 795 million in 2025 to USD 2,478 million by 2035, representing a CAGR of 12.03% during the forecast period till 2035.
Driven by numerous developmental breakthroughs and encouraging study results demonstrating the vast potential of adoptive cell therapies (ACT), including CAR-T cell therapies, TCR therapies, TILs and natural killer cell therapies, in the treatment of various complex disorders, this…
More Releases for Europe
2019 Strategy Consulting Market Analysis | McKinsey, The Boston Consulting Group …
Strategy Consulting Market reports also offer important insights which help the industry experts, product managers, CEOs, and business executives to draft their policies on various parameters including expansion, acquisition, and new product launch as well as analyzing and understanding the market trends
Need for strategic planning in highly competitive environment and to develop business capabilities to meet & exceed the emerging requirements are the major drivers which help in surging…
Strategy Consulting Market 2025 | Analysis By Top Key Players: Booz & Co. , Rola …
Global Strategy Consulting Market 2019-2025, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The key players covered in this study
McKinsey , The Boston Consulting Group , Bain & Company , Booz & Co. , Roland Berger Europe…
Digital Strategy Consulting Market is Thriving Worldwide with Deloitte, McKinsey …
A Digital Strategy is a form of strategic management and a business answer or response to a digital question, often best addressed as part of an overall business strategy. A digital strategy is often characterized by the application of new technologies to existing business activity and focus on the enablement of new digital capabilities to their business.
A new report as a Digital Strategy Consulting market that includes a comprehensive analysis…
Strategy Consulting Market 2019: By McKinsey, The Boston Consulting Group, Bain …
This report studies the global Strategy Consulting market, analyzes and researches the Strategy Consulting development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
• McKinsey
• The Boston Consulting Group
• Bain & Company
• Booz & Co.
• Roland Berger Europe
• Oliver Wyman Europe
• A.T. Kearney Europe
• Deloitte
• Accenture Europe
Get Sample Report@ https://www.reporthive.com/enquiry.php?id=1247388&req_type=smpl&utm_source=AB
Market segment by Type, the product can be split into
• Operations Consultants
• Business Strategy Consultants
• Investment Consultants
• Sales and…
Strategy Consulting Market Analysis 2018: McKinsey, The Boston Consulting Group, …
Orbis Research Present’s “Global Strategy Consulting Market” magnify the decision making potentiality and helps to create an effective counter strategies to gain competitive advantage.
The global Strategy Consulting status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Strategy Consulting development in United States, Europe and China.
In 2017, the global Strategy Consulting market size was million US$ and it is expected to reach million…
Influenza Vaccination Market Global Forecast 2018-25 Estimated with Top Key Play …
UpMarketResearch published an exclusive report on “Influenza Vaccination market” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 115 pages which highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. This report focuses on the Influenza Vaccination market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This…
